Testing a new drug combo for recurrent mouth cancer before surgery
Part of Cancer clinical trials.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is in the mouth or throat and has come back after treatment.
- You are between 18 and 75 years old.
- You are healthy enough for daily activities (ECOG score 0 or 1).
- Your doctor believes surgery is possible to remove the cancer.
- You have not had this type of immunotherapy (anti-PD-1) before.
- You have not had cancer treatment in the last 16 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (sintilimab and cetuximab) before and after surgery can improve outcomes for people with advanced mouth or throat cancer. It is for those who have not yet had treatment and whose tumors have a certain protein level (PD-L1 CPS >1).
This trial tests a new combination of two drugs (sacituzumab govitecan and toripalimab) given before surgery to shrink advanced oral cavity tumors. The goal is to see if this approach helps make surgery more effective and improves outcomes.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
Hear when a new Oropharyngeal Squamous Cell Carcinoma (SCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.